Rebates and drug costs: what the new proposal would mean

Forbes

28 February 2019 - The Trump administration is trying in myriad ways to answer demands from consumers for lower prescription drug prices—a topic that got serious attention before the Senate Finance Committee on Tuesday where top executives of seven major drug companies testified.

The president announced his “American Patients First” agenda in May, offering nearly 30 policy recommendations to modernise payment policies and expand competitive price negotiations, and the administration is forging ahead with action on these and many other recommendations.

The latest proposal from the Department of Health and Human Services—and one that got a number of questions from senators—is designed to shed sunlight on the complex deals involved in drug purchasing, targeting the “rebates” that flow through the $325-billion-a-year prescription drug spending pipeline.

Read Forbes article

Michael Wonder

Posted by:

Michael Wonder